Biotechnology

Data shows Beren Therapeutics' drug slows progression and boosts survival for infantile-onset NPC, a rare disorder with no approved US treatments.

The 2nd annual Chicago River Swim celebrates the river's historic cleanup, raises funds for ALS research, and promotes youth water safety in a new civic event.

One year post-approval, Neurotech's novel gene therapy implant is transforming patient lives and rewriting the playbook for biotech commercialization.

Global CRO Emerald Clinical Trials has won a major award for its patient-first strategies in the fast-growing, complex Asia-Pacific clinical trial market.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

The specialty infusion provider is the first to earn a rigorous new distinction, signaling a major leap forward in patient safety and quality of care.

The precision oncology firm reports a dramatic cut in net loss and a strategic pivot paying off, bolstered by a new U.S. patent for its cancer tech.

A plant-based gel that stops severe bleeding in seconds is being showcased to top trauma experts, signaling a major shift in emergency medicine.

With new clinical data and a clear path to Phase 2 trials, Gain Therapeutics' GT-02287 offers hope for a disease-modifying therapy for Parkinson's.

Ratio Therapeutics appoints Dr. Colin Hayward as CMO, a strategic move to advance its sarcoma trial and challenge leaders in the booming radiopharmaceutical market.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

Positive Phase 3 results for BBP-418 offer a potential first-ever treatment for LGMD2I/R9, a progressive muscle disease with no current therapies.

Industry pioneer Lee Leichter joins EdgeOne Medical, a strategic move to master the complex, high-stakes world of combination product regulation.

A novel compound, IRX4204, shows promise in preventing triple-negative breast cancer in lab studies, offering new hope for a safe, effective preventative.

The deal with Ahngook Pharm for its GMRx2 single-pill therapy marks a key step in a global strategy validated by recent US FDA approval.

The biopharma firm's new dividend policy reflects strong 2025 results and a dual strategy of rewarding shareholders while funding M&A and expansion.

With a massive new investment, Vima Therapeutics advances a first-in-class oral drug into Phase 2, offering new hope beyond injections and surgery.

A new study validating patient-reported outcomes in HAE is set to standardize clinical trials, strengthening the case for new oral therapies like deucrictibant.

With a strong cash position and new leadership, Artiva pivots its AlloNK® cell therapy to autoimmune disease, targeting a pivotal trial for RA in 2026.

A new fellowship at the Institut Pasteur aims to revolutionize public health by training scientists in what its founder calls the '3Ms': Money, Management, and Medicine.